WASHINGTON — The Supreme Court ensured Thursday that the abortion pill mifepristone can continue to be available by mail without an in-person appointment with a clinician.

Subscribe to read this story ad-free

Get unlimited access to ad-free articles and exclusive content.

A ruling by the New Orleans-based 5th U.S. Circuit Court of Appeals on May 1 had imperiled widespread access to the pill. Now, the Supreme Court has granted emergency requests brought by drugmakers Danco Laboratories and GenBioPro seeking to block that ruling.

The decision, a loss for the state of Louisiana, ensures there will not be any disruption to the availability of the drug as litigation continues. On May 4, in an order issued by conservative Justice Samuel Alito, the court had provisionally put the appeals court ruling on hold while the justices considered their next steps.

Two conservative justices, Clarence Thomas and Samuel Alito, dissented.

Thomas, noting that mailing mifepristone is illegal in Louisiana, took aim at the drugmakers, saying that they were not entitled to block a court order “based on lost profits from their criminal enterprise.”

In a separate opinion, Alito said the Biden’s administration’s decision to make mifepristone available by mail in 2023 was an attempt to “undermine” the court’s 2022 ruling that overturned abortion rights landmark Roe v. Wade.

“Louisiana’s efforts have been thwarted by certain medical providers, private organizations, and states that abhor laws like Louisiana’s and seek to undermine their enforcement,” Alito added.

Abortion-rights advocates welcomed the decision.

“The Supreme Court just did the bare minimum, but this ruling is a relief for patients who can continue to get the care they need. We know this is just one in a long line of attacks on our rights and our care,” Alexis McGill Johnson, president of the Planned Parenthood Action Fund, said in a statement.

The underlying case involves Louisiana’s challenge to the Food and Drug Administration’s decision during the Biden administration to allow mifepristone to be administered without in-person appointments, allowing access to the drug even in states where abortion is banned.

Anti-abortion groups have been pushing to reinstate the in-person dispensing requirement, alleging that taking mifepristone at home can be dangerous, although studies have found it to be safe and effective.

In asking the Supreme Court not to intervene, Louisiana Attorney General Liz Murrill, a Republican, wrote in court papers that even though abortion is almost totally banned in the state, up to 1,000 abortions a month are taking place because of mifepristone pills being mailed to women there.

Murrill bashed the court’s ruling in a statement Thursday evening.

“It’s shocking that the Supreme Court would block this common-sense return to medically ethical practices and oversight,” she said. “We will keep fighting.”

Erin Hawley, an attorney for the Alliance Defending Freedom, which is litigating the case alongside the state of Louisiana, said in a statement Thursday’s ruling, “It’s high time the Biden FDA be held accountable for the destruction it has caused with this high-risk drug.”

“Together with Louisiana Attorney General Liz Murrill’s office, we look forward to litigating our appeal at the 5th Circuit to protect mothers and their children,” Hawley added.

Mifepristone is used as part of a two-drug FDA-approved regimen that is now the most common form of abortion in the U.S. It is also used in miscarriage care.

The companies argued that Louisiana did not have standing, citing the Supreme Court’s 2024 decision that rejected a similar challenge to the FDA’s approvals of mifepristone on the grounds that the plaintiffs could not show they had suffered any injury.

Danco, which makes Mifeprex, the brand-name version of mifepristone, said in a statement that it is “pleased that a safe and effective drug Americans depend on will continue to be available while this litigation proceeds.”

Evan Masingil, CEO of GenBioPro, which markets the generic version of the pill, said the company is “committed to providing our evidence-based, essential medication to all who need it.”

In an unusual move, the Trump administration did not file a brief at the Supreme Court even though the FDA is technically a defendant in the case.

The government did file in the appeals court case, urging the court to rule in favor of the drug companies on the basis that Louisiana did not have legal standing to bring its claims.

The FDA is reviewing the safety protocols for mifepristone, meaning availability by mail could still be overturned. Louisiana’s lawsuit “not only would disrupt FDA’s ongoing review, and usurp FDA’s scientific role, but would also threaten chaos,” the Justice Department told the appeals court.

Following the Supreme Court decision, the FDA said on X that it will “press forward to complete its science-based safety review” of the pill.

Abortion is effectively banned altogether in 13 states, while several others have tight restrictions, according to the Guttmacher Institute, a research group that backs abortion rights.